Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 6, 2014, Pages 3123-3131

  Zhang, Jie ^a   Xu, Zhuding ^b   Zhou, Xingchun ^c   Zhang, Haibin ^b   Yang, Ning ^b   Wu, Yousheng ^c   Chen, Yibing ^c   Yang, Guangshun ^b   Ren, Tingting ^c  

^a CHENGDU MEDICAL COLLEGE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; MHC class I related chain

Indexed keywords

HLA ANTIGEN CLASS 1; MHC CLASS I-RELATED CHAIN A; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR ESCAPE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904311913     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Avila MA, Berasain C, Sangro B and Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866-3884.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273, e1261.
3. Bosch FX, Ribes J, Diaz M and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
4. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR and Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43: 979-992.
5. Feng JT, Shang S and Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene 2006; 25: 3810-3817.
6. Sherman M. Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis 2010; 42 Suppl 3: S215-222.
7. Arababadi MK, Nasiri Ahmadabadi B and Kennedy D. Current information on the immunologic status of occult hepatitis B infection. Transfusion 2012; 52: 1819-1826.
8. Smyth MJ, Hayakawa Y, Takeda K and Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
9. Biron CA, Nguyen KB, Pien GC, Cousens LP and Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220.
10. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002; 2: 957-964.
11. Degli-Esposti MA and Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005; 5: 112-124.
12. Cerwenka A and Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1: 41-49.
13. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-790.
14. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL and Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
15. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 1999; 96: 6879-6884.
16. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-568.
17. Bauer S, Willie ST, Spies T and Strong RK. Expression, purification, crystallization and crystallographic characterization of the human MHC class I related protein MICA. Acta Crystallogr D Biol Crystallogr 1998; 54: 451-453.
18. Maccalli C, Scaramuzza S and Parmiani G. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. Cancer Immunol Immunother 2009; 58: 801-808.
19. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S and Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43: 1013-1020.
20. Diefenbach A, Jensen ER, Jamieson AM and Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171.
21. Hayakawa Y. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets 2012; 16: 587-599.
22. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM and Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571-580.
23. Salih HR, Rammensee HG and Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-4102.
24. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG and Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68: 6368-6376.
25. Groh V, Wu J, Yee C and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
26. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B and Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171: 6891-6899.
27. Vetter CS, Groh V, thor Straten P, Spies T, Brocker EB and Becker JC. Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 2002; 118: 600-605.
28. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
29. Waldhauer I and Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27: 5932-5943.
30. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y and Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003; 104: 354-361.
31. Groh V, Steinle A, Bauer S and Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279: 1737-1740.
32. Yamamoto K, Fujiyama Y, Andoh A, Bamba T and Okabe H. Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim Biophys Acta 2001; 1526: 10-12.
33. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR and Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-260.
34. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T and Bukowski JF. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83-93.
35. Molinero LL, Fuertes MB, Fainboim L, Rabinovich GA and Zwirner NW. Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol 2003; 73: 815-822.
36. Kim S, Iizuka K, Aguila HL, Weissman IL and Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 2000; 97: 2731-2736.
37. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T and Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998; 83: 58-63.
38. Kawarabayashi N, Seki S, Hatsuse K, Ohkawa T, Koike Y, Aihara T, Habu Y, Nakagawa R, Ami K, Hiraide H and Mochizuki H. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000; 32: 962-969.